Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies

Previous studies have documented that FOLFOX and XELOX therapies negatively impact the metabolism of skeletal muscle and extra-muscle districts. This pilot study tested whether three-month FOLFOX or XELOX therapy produced changes in plasma amino acid levels (PAAL) (an estimation of whole-body amino...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of molecular sciences Jg. 25; H. 10; S. 5300
Hauptverfasser: Aquilani, Roberto, Brugnatelli, Silvia, Maestri, Roberto, Iadarola, Paolo, Corallo, Salvatore, Pagani, Anna, Serra, Francesco, Bellini, Anna, Buonocore, Daniela, Dossena, Maurizia, Boschi, Federica, Verri, Manuela
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland MDPI AG 01.05.2024
Schlagworte:
Adjuvant treatment
Adult
Aged
Amino acids
Amino Acids - blood
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Cancer patients
Cancer therapies
Capecitabine - therapeutic use
Chemotherapy
Colorectal cancer
Colorectal Neoplasms - blood
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - surgery
Creatinine
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
Drugs
Ethnicity
Female
Females
Fluorouracil - therapeutic use
Gender differences
Humans
Leucovorin - therapeutic use
Lipid Metabolism - drug effects
Lipid Peroxidation - drug effects
Lipids
Male
Malondialdehyde - blood
Metabolism
Middle Aged
Oncology, Experimental
Organoplatinum Compounds - therapeutic use
Oxaloacetates
Oxidation
Oxidation-Reduction
Oxidative stress
Pilot Projects
Plasma
Protein synthesis
Proteins
Ratios
Toxicity
plasma malondialdehyde changes
primary tumor location
colorectal cancer
FOLFOX and XELOX therapy
plasma amino acid changes
potential clinical implications
ISSN:1422-0067, 1661-6596, 1422-0067
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Previous studies have documented that FOLFOX and XELOX therapies negatively impact the metabolism of skeletal muscle and extra-muscle districts. This pilot study tested whether three-month FOLFOX or XELOX therapy produced changes in plasma amino acid levels (PAAL) (an estimation of whole-body amino acid metabolism) and in plasma levels of malondialdehyde (MDA), a marker of lipid hyper oxidation. Fourteen ambulatory, resected patients with colorectal cancer scheduled to receive FOLFOX (n = 9) or XELOX (n = 5) therapy, after overnight fasting, underwent peripheral venous blood sampling, to determine PAAL and MDA before, during, and at the end of three-month therapy. Fifteen healthy matched subjects (controls) only underwent measures of PAAL at baseline. The results showed changes in 87.5% of plasma essential amino acids (EAAs) and 38.4% of non-EAAs in patients treated with FOLFOX or XELOX. These changes in EAAs occurred in two opposite directions: EAAs decreased with FOLFOX and increased or did not decrease with XELOX (interactions: from p = 0.034 to p = 0.003). Baseline plasma MDA levels in both FOLFOX and XELOX patients were above the normal range of values, and increased, albeit not significantly, during therapy. In conclusion, three-month FOLFOX or XELOX therapy affected plasma EAAs differently but not the baseline MDA levels, which were already high.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms25105300